B7-1 and 4-1BB ligand expression on a myeloma cell line makes it possible to expand autologous tumor-specific cytotoxic T cells in vitro

This publication has 47 references indexed in Scilit:

• Identification of a new HLA-A2–restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma
  Experimental Hematology, 2006
• Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity
  Nature Reviews Immunology, 2004
• Unifying concepts in CD28, ICOS and CTLA4 co-receptor signalling
  Nature Reviews Immunology, 2003
• T cell activation with systemic agonistic antibody versus local 4-1BB ligand gene delivery combined with interleukin-12 eradicate liver metastases of breast cancer
  Gene Therapy, 2002
• Retrovirus-Mediated Gene Transfer in Primary T Lymphocytes: Influence of the Transduction/Selection Process and ofex VivoExpansion on the T Cell Receptor β Chain Hypervariable Region Repertoire
  Human Gene Therapy, 2000
• Anti–4-1bb Monoclonal Antibodies Abrogate T Cell–Dependent Humoral Immune Responses in Vivo through the Induction of Helper T Cell Anergy
  The Journal of Experimental Medicine, 1999
• Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: synergy with the CD28 co-stimulatory pathway
  European Journal of Immunology, 1998
• Developmental extinction of major histocompatibility complex class II gene expression in plasmocytes is mediated by silencing of the transactivator gene CIITA.
  The Journal of Experimental Medicine, 1994
• HLA-A31- and HLA-Aw68-restricted cytotoxic T cell responses to a single hepatitis B virus nucleocapsid epitope during acute viral hepatitis.
  The Journal of Experimental Medicine, 1993
• The defect in peripheral blood B-cell activation in patients with multiple myeloma is not due to a deficiency in the production of B-cell growth and differentiation factors
  Journal of Clinical Immunology, 1989